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ABSTRACT:  
Background: In 2012, an analysis of the Brazilian mortality database demonstrated under-
notification of anaphylaxis deaths due, at least in part, to difficult coding under the International 
Classification of Diseases (ICD)-10. This work triggered a cascade of strategic international actions 
supported by the Joint Allergy Academies and the ICD World Health Organization (WHO) 
representatives to update the classifications of allergic disorders for the ICD-11 revision. These 
efforts have resulted in the construction of the new “Allergic and hypersensitivity conditions” 
section under the “Disorders of the Immune system” chapter.  
Objective: To analyze the capacity of the new ICD-11 revision to capture anaphylaxis deaths.  
Methods: We re-estimated the anaphylaxis deaths that occurred in Brazil during the period 2008 to 
2010, utilizing this new framework and the database of the Brazilian mortality information system 
that had initially been extracted in May 2011. However, in 2016, a manual review of each of the 
3,638 records was performed. 
Results: We identified 639 anaphylaxis deaths, of which 95% were classified as “definitive 
anaphylaxis deaths”. In contrast to the 2012 published data, we found a higher number of cases; 
moreover, all 606 definitive anaphylaxis deaths would be considered as underlying causes of death 
utilizing the ICD-11 revision.  
Conclusion: This study is the first example of how the new “Allergic and hypersensitivity conditions” 
section of the forthcoming ICD-11 can improve the quality of official vital statistics data and the 
visibility of an important public health concern. This research will facilitate comprehensive, 
comparable population-based epidemiologic data collection on anaphylaxis.  
 




Anaphylaxis is defined as a severe life-threatening generalized or systemic hypersensitivity 
reaction (1). All anaphylaxis guidelines (1-4) consistently highlight the possibility of death during an 
anaphylactic episode. That said, there are only a limited number of population-based epidemiologic 
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notification can potentially lead to paucity of data and contribute to lack of recognition of the 
importance of anaphylaxis, which in turn can impact health care planning, including diagnosis, 
treatment and prevention, and hamper decision-making at many levels of the health care system.  
 Under-notification of anaphylaxis deaths is a well-recognized challenge. An important 
reason for this is the difficulty of coding anaphylaxis fatalities under the World Health Organization 
(WHO) International Classification of Diseases (ICD) system. In most countries, mortality statistics 
are routinely compiled according to regulations and recommendations adopted by the World Health 
Assembly (WHA). Causes of deaths are classified and grouped according to the ICD edition in use at 
the time and the information on death certificates is collected using the international form 
recommended by the WHO. However, a limited number of ICD-10 codes are considered to be valid 
for representing underlying causes of death on the current death certificates, and with regard to 
anaphylaxis as such, there are simply no valid codes (8, 9).  
In 2012, we estimated the magnitude of under-notification of anaphylaxis deaths using the 
information derived from both the underlying and the contributing causes of death data from the 
Brazilian Mortality Information System (Sistema de Informação sobre Mortalidade - SIM). In this 
study, we analyzed all 3,296,247 death records from 2008 to 2010 using ICD-10 and found a total of 
498 anaphylaxis deaths (Figure 1), with an average anaphylaxis death rate of 0.87/million/year, 
categorized as “definitive” or “possible” cases.  
The most striking observation from this study was that none of these deaths would have been 
attributed to anaphylaxis had we exclusively considered information from the underlying cause-of-
death field (8). The study called attention to the need for better coding not only for anaphylaxis 
deaths, but also for all allergic and hypersensitivity conditions, which would otherwise be 
misclassified in ICD-10 and ICD-11 (May 2014 version) (10). The timing of the study was opportune 
(2) as the ICD-11 revision process was underway. 
In order to create a more appropriate classification for allergic and hypersensitivity conditions 
in the ICD-11, a detailed action plan was coordinated based on scientific evidences for the necessity 
of changes (8, 10-19). Collaboration with the WHO ICD-11 revision governance is ongoing so far and 
all the efforts are being acknowledged by the Joint Allergy Academies. The main outcome of this 
process was the construction of the “Allergic and hypersensitivity conditions” section in the ICD-11 
Beta draft (16, 20). By consolidating all allergic conditions into one ICD-11 single section, as opposed 
to spreading them out over many ICD-10 chapters (Table 1) and by allowing all the relevant codes to 










This article is protected by copyright. All rights reserved. 
facilitate the use of such codes by clinicians, epidemiologists, and statisticians, as well as all data 
custodians and other relevant personnel. 
To further inform these deliberations and to follow the ICD-11 revision agenda, we report 
here on a re-analysis of anaphylaxis deaths in the Brazilian SIM evaluated in the 2012 publication (8) 
using the online ICD-11 Beta draft (March 2016 version) as the basis.  
 
METHODS 
In order to re-estimate the anaphylaxis deaths that occurred in Brazil during the period 2008 
to 2010 under the new framework of the ICD-11, we re-analyzed the database of the Brazilian SIM, 
which had been extracted on May 2011 using ICD-10. As in our previous study, out of the total 
3,296,247 records of all-causes mortality, we selected an initial sample of 3,638 records that listed 
any ICD-10 code related to anaphylaxis as the underlying or as contributing causes of death (Figure 
1).  
In contrast to the methodology used in our previous paper (8), we performed a manual review 
of all 3,638 records in order to reclassify them based on the online ICD-11 Beta draft (March 2016 
version). In order to do this, we carefully looked at the ICD-10 codes listed as the underlying or as 
contributing causes of death of each of the records and categorized them as “possible anaphylaxis 
deaths”, “definitive anaphylaxis deaths” or “deaths unrelated to anaphylaxis” using the logic of the 
ICD-11 framework (online ICD-11 Beta draft - March 2016 version). The methods have been 
reviewed by the co-authors. All records were independently evaluated by the first and last authors. 
Disagreements were resolved through open discussion and external review. The degree of inter-
rater agreement was assessed using Cohen’s kappa. Annual anaphylaxis mortality rate per 1 000 000 
population was calculated based on estimated population obtained from the Brazilian Institute of 
Geography and Statistics. 
We considered as “possible anaphylaxis deaths”, cases that had an isolated allergic or 
hypersensitivity clinical condition listed as a contributing cause of death (e.g., angioedema or 
urticaria). We decided that such conditions, unless presented together with other more specific 
anaphylaxis codes, could only rarely be considered an underlying cause of death. 
All records described as anaphylaxis or having an allergic or hypersensitivity condition as the 
underlying cause of death associated with the possible trigger as contributing mortality data were 
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immediate cause of death in the death certificates) were considered “death unrelated to 
anaphylaxis”, for example, cases of sepsis shock.  
 
RESULTS 
In the 2012 publication (8), we identified 498 cases of anaphylaxis deaths, 370 (75%) of which 
were categorized as “definitive anaphylaxis death”. In 2016, after the manual review of all 3,638 
records and re-analysis based on ICD-11, we identified 639 anaphylaxis deaths, of which 606 (95%) 
were classified as “definitive anaphylaxis deaths” (Figure 1). There was a high agreement on the 
classification procedures between the two coders (Cohen-kappa value 0.91). This higher number of 
cases includes all the 498 cases identified in our previous paper based on the ICD-10 classification 
system. We found an average rate of 1.12 (95% CI: 0.8–0.95) anaphylaxis deaths per million 
population per year, which is higher than the one from the previous publication estimated of 0.87 
deaths per million per year. 
When comparing cases found by using the ICD-11 and the ICD-10 classification systems, we 
found a similar demographic pattern (Table 2). Overall, most individuals who died from anaphylaxis 
were male (59%) and many were elderly (41%). Deaths typically took place in hospitals, which 
includes the Emergency Department and patients dead on arrival. Drugs were the leading cause.  
In contrast to our previous study in which 25.7% of records were categorized as “possible 
anaphylaxis death”, in the 2016 analysis, we had only 33 cases (5.2%) in this category.  
In stark contrast to the results presented in 2012, in which none of the identified deaths had 
“anaphylaxis” listed as the underlying cause, in the current analysis, following the logic of the new 
ICD-11 framework, anaphylaxis would be considered as the underlying cause of all 639 deaths.  
 
DISCUSSION 
This study represents the first attempt to prove that utilization of the new section titled 
“Allergic and hypersensitivity conditions” in ICD-11 can improve the quality of official vital statistics 
data and the visibility of an uncommon disease of public health concern. As in most countries, the 
information on death certificates is collected using the international form recommended by the 
WHO. The conditions and the sequence of events described on this form highlight some diseases 
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The WHO defines the underlying cause of death as: (i) the disease or injury which initiated the 
sequence of morbid events leading directly to death or (ii) the circumstances of the accident or 
violence which produced the fatal injury. Based on the ICD-10 codes, some external stimuli are 
considered as underlying causes-of-death, but anaphylaxis as such has never been prioritized as the 
underlying cause-of-death. In fact, having allergic and hypersensitivity conditions classified in a more 
detailed scheme in the ICD-11 (Table 1) and not as in ICD-10 into a specific chapter in the “External 
causes of morbidity and mortality” or in the “Injury, poisoning and certain other consequences of 
external causes” chapters allows for capture of more realistic anaphylaxis mortality data from now 
on. 
From a public health point of view, preventing the disease or injury identified as the 
underlying cause of fatality on death certificates results in the greatest health gain. Underlying cause 
of deaths statistics are widely used to determine priorities for health service and public health 
programs and for resource allocation. This study emphasizes the previous findings by providing 
objective public health data to substantiate mortality rules and health care decision-making changes. 
In addition to supporting the validation of the new structure, this study emphasizes the previous 
findings by providing objective public health data to substantiate health care changes and decision-
making. As an example, although we found 68% of cases recorded as occurring in hospital, 19% 
occurred outside health care establishments, reinforcing the need of making adrenaline auto-
injector devices available in all countries (1, 21, 22), including Brazil. 
We have found a higher proportion of “definitive anaphylaxis deaths” when compared to that 
of our previous publication (8), probably due to the use of a more detailed classification and a 
manual review of all 3,638 records. As a result, some cases previously classified as “deaths unrelated 
to anaphylaxis” have now been classified as “definite anaphylaxis deaths”. Importantly, there still 
may be additional anaphylaxis deaths in Brazil, as we only reviewed a proportion of cases that had 
any codes possibly related to anaphylaxis.  
There are two immediate consequences of the use of the new classification based on the logic 
of the ICD11: (i) the reported number of anaphylaxis deaths increased and (ii) all cases would be 
included in official mortality statistics. However, it is important to keep in mind that in order to apply 
the new classification, we still depend on the cause of death information available on death 
certificates. In other words, we are facing the same problems of data quality due to the inadequate 
completion of the death certificates by the end-users. This issue reflects lack of comprehension 
about the proper recording and interpretation of events, reinforcing the need for education 
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implement educational tools to cover this gap, following the ICD-11 logic.  Educational efforts will 
also help to address the decrease of under-recognition of anaphylaxis by patients, caregivers, and 
health professionals. 
In our analysis the death rate with the diagnosis anaphylaxis is approximately 25% higher, 
without overlooking a single death from the 2012 publication. Clearer is the effect on the accuracy 
reaching 95% for definite anaphylaxis when ICD11 was used. In a higher perspective, besides 
increasing the accuracy of vitals statistics data, unifying the allergic and hypersensitivity conditions 
into a single section of the ICD, endorsed by the WHO ICD governance bodies, can be considered a 
strong epidemiological, economical and political move that advocates in favor of the best diagnosis 
and management of allergic patients worldwide. 
As main limitations: (i) There is a risk of having the classification tuned up until the end of the 
revision process due to regular ICD-11 beta draft platform updates. (ii) Possibility that we cannot 
foresee on the manual classification, although we tried to minimize it by performing classification by 
independent investigators with third-party evaluation in cases of discordance.   
 
CONCLUSION 
This study represents the first attempt to prove that utilization of the new “Allergic and 
hypersensitivity conditions” section of the ICD-11 can improve the quality of official vital statistics 
data. The model presented can be considered as a springboard to facilitate comprehensive, 
comparable population-based epidemiologic data collection on anaphylaxis from a global 
perspective. 
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Table 1: Differences in the classification of the main allergic and hypersensitivity conditions in the ICD-10 and ICD-11 
MAIN HYPERSENSITIVITY 
DISORDERS (according to 
the EAACI-WAO revised 
nomenclature) 
ICD-10 VERSION 2016 
CORRESPONDING CHAPTER(S) 
ICD-11 BETA DRAFT “ALLERGIC AND 
HYPERSENSITIVITY CONDITIONS” (March 
2016 version) SECTION 
Asthma 
Chapter X: Diseases of the 
respiratory system 
“Allergic or hypersensitivity disorders 
involving the respiratory tract” 
Rhinitis 
Chapter X: Diseases of the 
respiratory system 
“Allergic or hypersensitivity disorders 
involving the respiratory tract” 
Conjunctivitis 
Chapter VII Diseases of the eye and 
adnexa 
“Allergic or hypersensitivity disorders 




Chapter XII Diseases of the skin and 
subcutaneous tissue 
“Allergic or hypersensitivity disorders 
involving skin and mucous membranes” 
Urticaria 
Chapter XII Diseases of the skin 
and subcutaneous tissue 
Angioedema 
Chapter XIX Injury, poisoning and 
certain other consequences of 
external causes 
Chapter III Diseases of the blood and 
blood-forming organs and certain 
disorders involving the immune 
mechanism 
Food hypersensitivity 
Chapter XIX Injury, poisoning and 
certain other consequences of 
external causes 
“Food hypersensitivity” section of the 
“Complex allergic or hypersensitivity 
conditions” 
Chapter XII Diseases of the skin and 
subcutaneous tissue 
Chapter XI Diseases of the digestive 
system 
 
Chapter XXI Factors influencing 
health status and contact with health 
services 
Drug hypersensitivity 
Chapter XIX Injury, poisoning and 
certain other consequences of 
external causes 
“Drug hypersensitivity” section of the 
“Complex allergic or hypersensitivity 
conditions” 
Chapter XX External causes of 
morbidity and mortality 
Chapter XII Diseases of the skin and 
subcutaneous tissue 
Chapter XXI Factors influencing 



































Chapter XX External causes of 
morbidity and mortality 
“Allergic or hypersensitivity reactions to 
arthropods” section of the “Complex allergic 
or hypersensitivity conditions” 
Anaphylaxis 
Chapter XIX Injury, poisoning and 
certain other consequences of 
external causes 
“Anaphylaxis” section subheadings: 
 Drug-induced anaphylaxis 
 Anaphylaxis due to insect venom 
 Anaphylaxis provoked by physical 
factors 
 Anaphylaxis due to inhaled 
allergens 
 Anaphylaxis due to contact with 
allergens 
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Table 2: Demographic characterization of anaphylaxis deaths recorded from 2008 to 2010 in the Brazilian Mortality Information System   
DEMOGRAPHIC 
DATA 
ANAPHYLAXIS DEATHS ACCORDING TO THE 2012 
PUBLICATION, USING THE ICD-10 
ANAPHYLAXIS DEATHS REVIEWED BASED ON THE 





N = 128 (%) 
Definitive 
anaphylaxis deaths 
N = 370 (%) 
Total 
N = 498 (%) 
Possible anaphylaxis 
deaths 




N = 606 (%) 
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Children (0-15) 

































Place of occurrence 
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Brazilian Mortality Information System (SIM), data extracted May 2011 
 
Total 3,296,247 records, from 2008 to 2010 
2012 analysis (Allergy, 2012), based on 




N = 128 
“Definitive anaphylaxis 
deaths” 
N = 370 
3,638 deaths had any ICD-10 code related to anaphylaxis listed as 
the underlying or as contributing causes of death 
 
2016 analysis, based on ICD-11 Beta Draft  




(Manual review of all codes 
recorded on any lines parts 1 





(Specific anaphylaxis codes – 
T780, T782, T805 and T886 





(Specific anaphylaxis codes as 
contributing cause of death + 
Manual review of each description 




(Manual review of each description 
in death certificates: iso lated 
description of allergic or 
hypersensitivity clinical 
presentations described as 
contributing cause of death) 
“Possible anaphylaxis 
deaths” 
N = 33 
“Definitive anaphylaxis 
deaths” 
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